HS235 / 35Pharma - LARVOL DELTA

HS235, a Novel Activin Signaling Inhibitor, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension and Heart Failure (AHA 2025) - "Briefly, mice underwent TAC surgery, recovered for 2 weeks, and were then treated with vehicle, HS235, or wild-type ActRIIA-Fc (a sotatercept surrogate) for 4 weeks. HS235 improved PH, HF, body composition and exercise tolerance in in vivo models. These results demonstrate the differentiated therapeutic profile of HS235 and support its further development as a novel treatment of cardiopulmonary and cardiometabolic diseases."

Preclinical • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ACVR2A

HS235, A Novel Lean Mass-Preserving Treatment for Obesogenic HF with Preserved Ejection Fraction (OBESITY WEEK 2025) - "These data demonstrate that HS235 represents a novel approach to treating obesity and associated co-morbidities in a manner that is complementary and orthogonal to currently approved incretin-based medications. Specifically, these data support the development of HS235 in obesogenic HFpEF and as a fat-selective anti-obesity agent."

Cardiovascular • Congestive Heart Failure • Fibrosis • Genetic Disorders • Heart Failure • Immunology • Obesity • TGFB1

HS235, a Novel Activin Signaling Inhibitor, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension (PH) and Heart Failure (HF) (ERS 2025) - "HS235 improved PH, HF, metabolism and exercise tolerance in in vivo models. These results demonstrate the differentiated therapeutic profile of HS235 and support its further development as a novel treatment of cardiopulmonary and cardiometabolic diseases."

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ACVR2A

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: 35Pharma Inc

New P1 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF) (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: 35Pharma Inc

New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

HS235, A Novel Lean Mass-Preserving Treatment for Obesogenic Heart Failure with Preserved Ejection Fraction with Pleiotropic Metabolic Effects (ENDO 2025) - "These data demonstrate that HS235 represents a novel approach to treating obesity and associated co-morbidities in a manner that is complementary and orthogonal to currently approved incretin-based medications. Specifically, these data support the development of HS235 in obesogenic HFpEF and as a fat-selective anti-obesity agent."

Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • TGFB1

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: 35Pharma Inc

New P1 trial • Genetic Disorders • Obesity